Valuation: Acrux Limited

Market Cap 6.16M 4.31M 3.78M 3.49M 3.21M 6.06M 416M 41.77M 16.37M 203M 16.19M 15.84M 701M P/E 2024
-3.44x
P/E 2025 -0.95x
Enterprise Value 8.93M 6.25M 5.48M 5.07M 4.66M 8.79M 603M 60.57M 23.74M 295M 23.48M 22.96M 1.02B EV / Sales 2024
4.09x
EV / Sales 2025 7.81x
Free-Float
78.27%
Yield 2024 *
-
Yield 2025 -
1 day+0.93%
3 months+275.56%
6 months+275.56%
Current year+3.68%
Current year 0
Extreme 0.0045
0.02
1 year 0
Extreme 0.001
0.05
3 years 0
Extreme 0.001
0.06
5 years 0
Extreme 0.001
0.1
10 years 0
Extreme 0.001
0.28
Manager TitleAgeSince
Chief Executive Officer - 2025-05-31
Director of Finance/CFO - 2021-06-20
Chief Tech/Sci/R&D Officer - 2015-02-14
Director TitleAgeSince
Chairman 74 2005-12-31
Director/Board Member - 2013-09-30
Director/Board Member 70 2016-05-31
Change 5-day change 1-year change 3-year change Capi.($)
+0.93%-.--% - - 4.3M
+1.23%+1.82%+15.52%+78.24% 48.15B
+0.50%+0.50%+69.27%+110.57% 35.59B
+1.61%+1.04%-2.75%+36.44% 11.9B
+0.46%+1.56%+17.85%+86.06% 11.85B
-0.37%+0.94%+34.42%+136.73% 9.31B
-0.39%-0.68%+52.77%-5.53% 7.02B
-0.42%+0.25%+16.96%+34.73% 6.91B
-.--%+0.14% - - 6.79B
+0.18%-2.69%+0.63%+202.37% 6.55B
Average +0.37%-0.65%+25.58%+84.95% 16.01B
Weighted average by Cap. +0.65%-0.70%+30.62%+87.09%

Financials

2024 2025
Net sales 5.09M 3.56M 3.12M 2.89M 2.66M 5.01M 344M 34.53M 13.53M 168M 13.38M 13.09M 579M 1.19M 833K 730K 675K 621K 1.17M 80.33M 8.07M 3.16M 39.3M 3.13M 3.06M 135M
Net income -5.8M -4.06M -3.56M -3.29M -3.03M -5.71M -392M -39.33M -15.42M -192M -15.25M -14.91M -660M -5.94M -4.16M -3.65M -3.37M -3.1M -5.85M -401M -40.32M -15.8M -196M -15.63M -15.29M -677M
Net Debt 759K 531K 466K 430K 396K 747K 51.24M 5.15M 2.02M 25.07M 2M 1.95M 86.37M 2.77M 1.94M 1.7M 1.57M 1.45M 2.73M 187M 18.8M 7.37M 91.56M 7.29M 7.13M 315M
Logo Acrux Limited
Acrux Limited is an Australia-based specialty pharmaceutical company. The Company is engaged in developing and commercializing a pipeline of topically applied pharmaceutical products. Its products include Lidocaine and Prilocaine Cream, USP 2.5%/2.5%, Lenzetto, Evamist, Dapsone Gel, 5% and Testosterone Topical Solution, 30 mg / 1.5 ml. Lidocaine and Prilocaine Cream USP (a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) is indicated as a topical anesthetic for use on normal intact skin for local analgesia and genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia. Lenzetto (estradiol 1.53 mg/spray, transdermal spray, solution) is an estradiol spray for women which is used to treat moderate to severe hot flushes commonly associated with menopause. Testosterone Topical Solution is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.
Employees
43

Annual profits - Rate of surprise